Novavax, Inc. (NASDAQ:NVAX) Shares Acquired by Rafferty Asset Management LLC

Rafferty Asset Management LLC increased its position in shares of Novavax, Inc. (NASDAQ:NVAXFree Report) by 62.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,611,840 shares of the biopharmaceutical company’s stock after purchasing an additional 619,370 shares during the period. Rafferty Asset Management LLC owned 1.36% of Novavax worth $7,737,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in shares of Novavax by 11.1% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 40,533 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 4,045 shares during the last quarter. PEAK6 Investments LLC raised its stake in shares of Novavax by 47.7% in the 3rd quarter. PEAK6 Investments LLC now owns 30,085 shares of the biopharmaceutical company’s stock valued at $218,000 after acquiring an additional 9,714 shares during the period. Hodges Capital Management Inc. acquired a new position in shares of Novavax in the 3rd quarter worth approximately $72,000. Nomura Holdings Inc. acquired a new position in Novavax during the third quarter worth $74,000. Finally, Private Advisor Group LLC acquired a new position in Novavax during the third quarter worth $81,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Insider Activity at Novavax

In other news, insider Filip Dubovsky sold 47,312 shares of the business’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $13.90, for a total transaction of $657,636.80. Following the transaction, the insider now directly owns 38,953 shares in the company, valued at $541,446.70. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on NVAX. HC Wainwright reissued a “buy” rating and set a $19.00 target price on shares of Novavax in a research note on Monday, May 13th. TD Cowen increased their price objective on Novavax from $5.00 to $10.00 and gave the company a “hold” rating in a research note on Monday, May 13th. Bank of America upgraded Novavax from an “underperform” rating to a “neutral” rating and lifted their price objective for the company from $4.00 to $12.00 in a research note on Friday, May 10th. B. Riley boosted their price objective on Novavax from $11.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, May 23rd. Finally, JPMorgan Chase & Co. upgraded shares of Novavax from an “underweight” rating to a “neutral” rating in a report on Friday, May 10th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Novavax has a consensus rating of “Hold” and a consensus price target of $17.50.

View Our Latest Research Report on Novavax

Novavax Price Performance

Shares of NVAX opened at $20.97 on Thursday. Novavax, Inc. has a 1-year low of $3.53 and a 1-year high of $22.24. The firm has a fifty day moving average price of $8.41 and a 200 day moving average price of $6.10.

Novavax (NASDAQ:NVAXGet Free Report) last issued its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.01). The business had revenue of $93.90 million during the quarter, compared to the consensus estimate of $71.32 million. During the same period in the prior year, the company posted ($3.41) EPS. The company’s revenue was up 15.9% compared to the same quarter last year. As a group, equities analysts expect that Novavax, Inc. will post 0.36 EPS for the current fiscal year.

About Novavax

(Free Report)

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

Read More

Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.